Company intelligence / Profile preview

Inscripta

Boulder, Colorado, United Statesmuse.mu ↗

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

The company developed ForgeCraft™, a next-generation CRISPR-based digital genome engineering platform that enables high-throughput, precise genomic modifications. The technology accelerates research in synthetic biology by automating complex gene editing tasks on a benchtop system. The company has transitioned from Muse Bio to become part of Inscripta Inc., which continues commercial operations with expanded offerings in digital genome engineering. No clinical results reported as it does not develop therapeutics directly.

Modalities: CRISPR-based therapyDevice
Industry: Non-Drug Biotech

Partnerships

dsm-firmenich (as Inscripta)

Beyond the preview

Go deeper on Inscripta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inscripta.

Explore the full profile